Iron dextran

Names

[ CAS No. ]:
9004-66-4

[ Name ]:
Iron dextran

[Synonym ]:
MFCD00081553
Ferric hydroxide dextran complex

Biological Activity

[Description]:

Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals[1][2].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

[In Vivo]

Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature[1]. Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration[1]. Animal Model: Wild-type (WT) and RS-HepcKO mice[1]. Dosage: IP. Administration: 300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks. Result: Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.

[References]

[1]. Wanting Shu, et al. Iron Accumulates in Retinal Vascular Endothelial Cells But Has Minimal Retinal Penetration After IP Iron Dextran Injection in Mice. Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4378-4387.

[2]. D. R. ZIMMERMAN, et al. INJECTABLE IRON-DEXTRAN AND SEVERAL ORAL IRON TREATMENTS FOR THE PREVENTION OF IRONDEFICIENCY ANEMIA OF BABY PIGS x. Journal of Animal Science, Volume 18, Issue 4, November 1959, Pages 1409–1415.

Chemical & Physical Properties

[ Molecular Formula ]:
H₂O₄S_.Fe

[ Molecular Weight ]:
1347.364

[ Exact Mass ]:
1346.576050

[ Appearance of Characters ]:
solution

Safety Information

[ Symbol ]:

GHS07, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H317-H350

[ Precautionary Statements ]:
P201-P280-P308 + P313

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R40;R42/43

[ Safety Phrases ]:
S23;S26;S45;S36/S37/S39

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
-

[ RTECS ]:
NI2200000

Articles

Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status

Exp. Hematol. 41(6) , 539-46, (2013)

Numerous studies have shown the antiproliferative effect of iron chelating agents (ICAs), which have been used traditionally in patients with secondary iron overload (SIO). Because the in vivo model f...

[Importance of the different i.v. iron generations for everyday medical practice].

MMW Fortschr. Med. 155 Suppl 1 , 18-24, (2013)

Iron deficiency and anaemia occur in particular in women or as comorbid conditions to a varietyof chronic diseases. Besides oral preparations, parenteral iron therapies are also available for the trea...

Use of intravenous iron supplementation in chronic kidney disease: an update.

Iran. J. Kidney Dis. 7(1) , 9-22, (2013)

Iron deficiency is an important clinical concern in chronic kidney disease (CKD), giving rise to iron-deficiency anemia and impaired cellular function. Oral supplementation, in particular with ferrous...